We are developing potential medicines that improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.
Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.
- Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
- Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference
- Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference